Home > Healthcare & Medical Devices > Tuberculosis Diagnostics Market

Tuberculosis Diagnostics Market Size, COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2028

  • Report ID: GMI4079

Tuberculosis Diagnostics Market Size is estimated to exhibit a substantial CAGR from 2022 to 2028, owing to the soaring demand for different types of tests comprising TB blood tests and TB skin tests. While a positive test merely indicates infection with TB bacteria, it does not confirm if a person has progressed to TB disease or has latent TB infection. This factor is propelling the demand for other tests such as sample of sputum and chest x-ray.
 

By testing type, nucleic acid testing segment is set to account for a lucrative revenue in the market share through 2028. This rise is chiefly attributed to the increasing advocation of these procedures by several regulators. For instance, according to the recommendations of the CDC, NAA testing should be treated as a priority test in the U.S. and all public health TB programs and clinicians should get access to molecular tests to aid in TB diagnosis. Additionally, it has also recommended that NAA testing should be adopted as the standard practice for TB suspects. These factors are expected to drive segment growth during the forecast period.
 

Based on end use, the market value is predicted to register commendable growth from the hospitals segment during the forecast period. This is on account of the rising demand for diagnostic procedures in hospital settings and the increasing pervasiveness of MDR (multi-drug resistant) tuberculosis. The segment expansion is further led by the escalating development of healthcare infrastructure and increasing investments by numerous governments for reducing the burden of tuberculosis.
 

Asia Pacific tuberculosis diagnostics market share is anticipated to record remarkable expansion through 2028. This growth is attributed to the increasing number of innovations in the field of TB diagnostics. Numerous products on the market range from laboratory-based molecular diagnostics to AI (artificial intelligence) for CXR (chest x-ray) interpretation. In 2021, analysis of the results of studies of Lunit from South Korea and Qure.ai from India contributed to the recommendations of the World Health Organization for CAD (computer-aided detection) of CXRs.
 

Major companies in the market comprise BioMerieux SA, AdvaCare Pharma, Hologic Corporation, Abbott Laboratories, Roche AG, Qiagen, Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Cepheid, Hain Lifescience. These participants are focusing on acquisitions, mergers, product launches, partnerships, and collaborations for securing a competitive edge in the market.
 

For instance, in July 2021, Roche announced that the cobas MTB-RIF/INH and cobas MTB tests for deployment on the cobas 6800/8800 systems have been included as part of the updated WHO policy guidelines on NAATs for the detection of drug-resistant TB and tuberculosis. The new guidance extends the number of rapid molecular tests that are available to national TB programs in high-burden countries, in turn allowing multi-partner diagnostic approaches that can benefit communities and patients.
 

Assessing the impact of COVID on tuberculosis diagnostics market growth

In the pandemic period, tuberculosis and COVID-19 are projected to pose a dual threat in light of the prevalent poverty and social inequities. The SARS-CoV-2 outbreak has led to a mass setback to progress in reaching tuberculosis targets, making it imperative to leverage innovative models for the improvement of tuberculosis control and care. As per statistics, around 1 million people have found it difficult to get diagnosed with tuberculosis during the pandemic period. This is driving the demand for numerous tuberculosis diagnostic tests and procedures across various regions.
 

The market research report of tuberculosis diagnostics includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2028 for the following segments:

Market, by Test Type

  • Tuberculin skin tests
  • Interferon-gamma release assays (IGRAs)
  • Smear microscopy
  • Serological antibody-based tests
  • Culture
  • Identification or speciation tests
  • Nucleic acid amplification tests (NAATs)
  • Phenotypic drug susceptibility tests
  • Adenosine deaminase (ADA) test.

Market, by End-use

  • Hospitals
    • Public
    • Private
  • Diagnostic Centers
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Mexico
    • Brazil
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
       

What Information does this report contain?

Historical data coverage: 2017 to 2021; Growth Projections: 2022 to 2028.
Expert analysis: industry, governing, innovation and technological trends; factors impacting development; drawbacks, SWOT.
6-7 year performance forecasts: major segments covering applications, top products and geographies.
Competitive landscape reporting: market leaders and important players, competencies and capacities of these companies in terms of production as well as sustainability and prospects.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Budget constraints? Get in touch with us for special pricing

Request Discount

Our Market Research Reports Include:

  • Market snapshot
  • Market Segmentation
  • Value Chain Analysis
  • Growth Dynamics
  • Potential Market Opportunities
  • Regulatory Overview
  • Technology Evolution
  • Innovation & Sustainability